Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 56
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT02831972 | Drug-Drug Interaction Study of AG120 in Healthy Subjects | ||
| NCT03548220 | A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD) | ||
| NCT04536792 | A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease | ||
| NCT06648824 | Study of How Mitapivat Affects Midazolam Blood Levels in Healthy Participants | ||
| NCT04472832 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mitapivat (AG-348) in Healthy Adult Participants | ||
| NCT04565678 | A Study to Assess the Relative Bioavailability and Effect of Food on the Coated Granule Formulation of Mitapivat in Healthy Participants | ||
| NCT03960502 | A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881 | ||
| NCT05610657 | A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function | ||
| NCT03071770 | Japanese Bridging Study of Ivosidenib (AG-120) in Healthy Subjects | ||
| NCT03481738 | Pyruvate Kinase Deficiency Global Longitudinal Registry | ||
| NCT07075640 | A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants | ||
| NCT05031780 | A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP) | ||
| NCT03361358 | Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma | ||
| NCT06745271 | A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Tebapivat is Made Available in the Body in Healthy Participants | ||
| NCT02053480 | Pyruvate Kinase Deficiency Natural History Study | ||
| NCT02492737 | Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation | ||
| NCT04145128 | A Study to Evaluate AG-881 in Healthy Japanese and Non-Asian Participants | ||
| NCT04696393 | A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult Participants | ||
| NCT04128787 | A Study to Compare the Relative Bioavailability of Two AG-881 Formulations and Evaluate the Effect of Food and Omeprazole on the Pharmacokinetics of AG-881 | ||
| NCT03397329 | Study to Evaluate the Relative Bioavailability and Safety of the AG-348 Tablet and Capsule Formulations in Healthy Adults | ||
| NCT03853798 | Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007 | ||
| NCT02579707 | Food Effect Study of AG120 in Healthy Subjects | ||
| NCT06286046 | A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy | ||
| NCT07055243 | To Assess Safety of Mitapivat and Provide Proof of Concept of the Efficacy of the Drug in Patients With RBC Membranopathies or CDAII. | ||
| NCT02489513 | Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120 | ||
| NCT04015687 | A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy Adults | ||
| NCT03559699 | A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD) | ||
| NCT03834584 | A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma | ||
| NCT02630927 | A Safety and Tolerability Study of AG-519 in Healthy Subjects | ||
| NCT05175105 | A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period | ||
| NCT04056910 | Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors | ||
| NCT04770779 | A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) | ||
| NCT07241234 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria | ||
| NCT03564821 | IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation | ||
| NCT04902833 | Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms | ||
| NCT03692052 | A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia | ||
| NCT01915498 | Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation | ||
| NCT04964323 | Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported Outcomes (PRO) | ||
| NCT04000165 | A Dose-Finding Study of AG-348 in Sickle Cell Disease | ||
| NCT03703505 | A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C]AG-348 and Concomitant Single Intravenous Microdose of [13C6]AG-348 | ||
| NCT05777993 | A Study to Provide Continued Access to Mitapivat for Participants Who Previously Completed an Agios-Sponsored Mitapivat Study | ||
| NCT02476916 | A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) Deficiency | ||
| NCT02108106 | A Phase I Study of AG-348 in Healthy Volunteers | ||
| NCT03245424 | Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation | ||
| NCT05490446 | A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) | ||
| NCT02218346 | Food Effect Study of AG-221 in Healthy Male Subjects | ||
| NCT06924970 | A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD) | ||
| NCT04278781 | AG-120 in People With IDH1 Mutant Chondrosarcoma | ||
| NCT03282513 | A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function | ||
| NCT02149966 | A Phase I Study of AG-348 in Healthy Volunteers |
